Scientists have made a breakthrough in physics. They succeeded in transporting heat maximally effectively ten thousand times further than ever before. The discovery may lead to a giant leap in the development of quantum computers.
After six years of painstaking effort, a group of materials scientists believe the tiny sheets of the semiconductor zinc oxide they're growing could have huge implications for the future of a host of electronic and biomedical devices.
Advancements in nanotechnology could fundamentally change global approaches to manufacturing, medicine, healthcare, and the environment. In this lecture Dr Eric Drexler, Senior Visiting Fellow, Oxford Martin School, will look at current advances in the field of advanced nanotechnology, and the impacts and potential applications of their widespread implementation, and Dr Sonia Trigueros, Co-Director of the Oxford Martin Programme on Nanotechnology, and Oxford Martin Senior Fellow, will consider how targeted nanomedicine could change how we treat disease in the future.
The iron Fe2+ atom embedded in a semiconductor exhibits a single non-degenerate ground state of zero magnetic moment. A team of scientistss has just shown that by using sufficiently large strain it is possible to tailor the energy spectrum of the iron atom to obtain doubly degenerate (magnetic) ground state.
Super-sharp images from within the human body made through tiny endoscopes have come a step closer to reality. An advanced wavefront shaping method combined with unique optical fibres make it possible to focus lensless light at an unparalleled resolution.
New transparent metamaterials under development could make possible computer chips and interconnecting circuits that use light instead of electrons to process and transmit data, representing a potential leap in performance.
The complement system, the human body's first line of defense against blood-borne intruders, is blamed for infusion-related reactions to nanomedicines, but the conventional models used to predict the risk of cardiopulmonary side effects in response to nanopharmaceuticals might not well represent what actually occurs in humans, according to a new article.